Clinical Trial

A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury

Recruiting
View on ClinicalTrials.gov →
Summary
The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-03.
Status change: Not Yet Recruiting → Recruiting 2026-01-04
Trial Details
NCT Number NCT07107932
Lead Sponsor Zhuhai Trinomab Pharmaceutical Co., Ltd.
Conditions Tetanus
Enrollment 10,000 participants
Start Date 2025-07-31
Primary Completion 2029-03-30 (estimated)
Study Completion 2029-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-06